221 related articles for article (PubMed ID: 37049742)
1. Study of
Biswas P; Bibi S; Yousafi Q; Mehmood A; Saleem S; Ihsan A; Dey D; Hasan Zilani MN; Hasan MN; Saleem R; Awaji AA; Fahmy UA; Abdel-Daim MM
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049742
[TBL] [Abstract][Full Text] [Related]
2. Analysis of SYK Gene as a Prognostic Biomarker and Suggested Potential Bioactive Phytochemicals as an Alternative Therapeutic Option for Colorectal Cancer: An In-Silico Pharmaco-Informatics Investigation.
Biswas P; Dey D; Rahman A; Islam MA; Susmi TF; Kaium MA; Hasan MN; Rahman MDH; Mahmud S; Saleh MA; Paul P; Rahman MR; Al Saber M; Song H; Rahman MA; Kim B
J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575665
[TBL] [Abstract][Full Text] [Related]
3. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways.
Chen SR; Cai WP; Dai XJ; Guo AS; Chen HP; Lin GS; Lin RS
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3461-3470. PubMed ID: 31081101
[TBL] [Abstract][Full Text] [Related]
4. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
6. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
7. P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma.
Cui W; Wu R; Cao H; Gao J; Wang X; Ren Q
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):622-4, 635. PubMed ID: 16696307
[TBL] [Abstract][Full Text] [Related]
8. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
[TBL] [Abstract][Full Text] [Related]
9. Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53.
Yamada S; Kanno H; Kawahara N
J Neurooncol; 2012 Aug; 109(1):7-14. PubMed ID: 22528789
[TBL] [Abstract][Full Text] [Related]
10. Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study.
Oyedele AK; Adelusi TI; Ogunlana AT; Ayoola MA; Adeyemi RO; Babalola MO; Ayorinde JB; Isong JA; Ajasa TO; Boyenle ID
J Biomol Struct Dyn; 2023; 41(12):5817-5826. PubMed ID: 35822492
[TBL] [Abstract][Full Text] [Related]
11. miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Chen Q; Wang W; Chen S; Chen X; Lin Y
Cell Mol Biol Lett; 2021 May; 26(1):21. PubMed ID: 34044759
[TBL] [Abstract][Full Text] [Related]
12. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
13. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
14. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
[TBL] [Abstract][Full Text] [Related]
15. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
16. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
17. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
19. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Tong H; Zhao K; Zhang J; Zhu J; Xiao J
Drug Des Devel Ther; 2019; 13():317-326. PubMed ID: 30679904
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis.
Tsuiki H; Nishi T; Takeshima H; Yano S; Nakamura H; Makino K; Kuratsu J
Neurol Med Chir (Tokyo); 2007 May; 47(5):203-8; discussion 208-9. PubMed ID: 17527046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
